ArticleOphthalmology science
Age-Related Scattered Hypofluorescent Spots as an Adverse Prognostic Factor for Polypoidal Choroidal Vasculopathy.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Choroidal vascular biomarkers for macular neovascularization in chronic central serous chorioretinopathy: insights from widefield indocyanine green angiography.Eye and vision (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Polypoidal choroidal vasculopathy (PCV) demonstrates significant prognostic variability, and the impact of age-related scattered hypofluorescent spots observed in late-phase indocyanine green angiography (ASHS-LIA) on the prognosis of PCV remains under-researched. This study aims to investigate the association between ASHS-LIA in PCV and prognosis using the AdaBoost machine learning model. Design: A cross-sectional study. Participants: The study included patients diagnosed with PCV and treated with anti-VEGF therapy at 2 medical institutions between 2012 and 2021. Methods: We conducted a retrospective analysis of the clinical characteristics, anti-VEGF treatment history, and outcomes of the participants, classifying them based on the presence or absence of ASHS-LIA. An AdaBoost meta-estimator was applied to predict prognosis, including disease stability, injection frequency, and time to first remission, utilizing features selected through principal component analysis. Main Outcome Measures: The prognostic significance of ASHS-LIA was assessed by feature importance, with the mean decrease in impurity serving as the evaluation metric. Results: Of 57 eyes with PCV, 31 exhibited ASHS-LIA and 26 did not. Compared with the non-ASHS-LIA group, the ASHS-LIA group had fewer patients who achieved a super-stable status without recurrence for >18 months postremission ( Conclusions: Machine learning analysis identified ASHS-LIA as a negative prognostic factor in PCV, correlating with reduced disease stability, higher recurrence rates, and increased treatment requirements. These findings suggest that ASHS-LIA could serve as a valuable marker for assessing prognosis and guiding treatment strategies in PCV management. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.